Profiling critical cancer gene mutations in clinical tumor samples

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Accurate detection of cancer gene mutations in tumors is crucial for predicting patient outcomes and guiding treatment.
• High-throughput mutation profiling is an underdeveloped diagnostic approach in clinical settings.
• A novel genotyping and validation algorithm enables robust tumor mutation profiling.

Purpose of the Study:

• To implement and validate an optimized mutation profiling platform for clinical use.
• To interrogate a large panel of cancer gene mutations for diagnostic and therapeutic insights.
• To assess the platform's performance on diverse clinical cancer samples.

Main Methods:

• Developed and implemented the "OncoMap" platform to analyze approximately 400 mutations in 33 oncogenes and tumor suppressors.
• Tested OncoMap performance using DNA from fresh frozen and FFPE clinical cancer tissues.
• Conducted in-depth analysis on pediatric gliomas, including molecular stratification based on BRAF mutations.

Main Results:

• OncoMap demonstrated high sensitivity (93.8% in fresh frozen, 89.3% in FFPE) and specificity (100% in fresh frozen, 99.4% in FFPE).
• Detected known mutations at expected frequencies and identified novel mutations predicting response or resistance to targeted therapies.
• Supported molecular stratification of pediatric low-grade gliomas based on BRAF mutations with potential clinical impact.

Conclusions:

• High-throughput mutation profiling is clinically feasible for interrogating a large panel of actionable cancer gene mutations.
• This approach has the potential to be integrated into cancer epidemiologic studies.
• Future applications include clinical decision-making to guide the use of targeted anticancer agents.